Risk Factors for Coronary Heart Disease in Patients Treated for Human Immunodeficiency Virus Infection Compared with the General Population
Top Cited Papers
Open Access
- 15 July 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (2) , 292-298
- https://doi.org/10.1086/375844
Abstract
The distribution of risk factors for cardiovascular disease in patients aged 35–44 years who were treated for human immunodeficiency virus type 1 (HIV-1) infection was compared with that for a population-based cohort. HIV-1-infected men treated with a protease inhibitor-containing regimen (n = 223), compared with HIV-1-uninfected men (n = 527), were characterized by a lower prevalence of hypertension, a lower mean high-density lipoprotein cholesterol level, a higher prevalence of smoking, a higher mean waist-to-hip ratio, and a higher mean triglyceride level. No difference was found for total plasma or low-density cholesterol levels, nor for the prevalence of diabetes. Similar trends were observed among female subjects. The predicted risk of coronary heart disease was greater among HIV-1-infected men (relative risk [RR], 1.20) and women (RR, 1.59; P < 10-6 for both), compared with the HIV-1-uninfected cohort. The estimated attributable risks due to smoking were 65% and 29% for HIV-1-infected men and women, respectively. Because most HIV-1-infected people will ultimately need antiretroviral therapy, risk factors for cardiovascular disease should be determined at the initiation of treatment, and interventions should be considered for all patients who have them.Keywords
This publication has 20 references indexed in Scilit:
- Factors Related to Lipodystrophy and Metabolic Alterations in Patients with Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2002
- Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapyAIDS, 2001
- Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populationsThe Lancet, 2000
- Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease InhibitorsCirculation, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Severe premature coronary artery disease with protease inhibitorsThe Lancet, 1998
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991
- Hypertriglyceridemia in the acquired immunodeficiency syndromeThe American Journal of Medicine, 1989